TheraRadar

Can-Fite

Pre-Approval PRO BETA
19
Total Trials
6
Phase 3
14
Phase 2
3
Recruiting
218
Score

Pipeline by Phase

Phase 3
6
Phase 2
14
Phase 1
2

Therapeutic Focus

Plaque Psoriasis Hepatocellular Carcinoma Rheumatoid Arthritis Lowe Syndrome Cirrhosis

Clinical Trials (19)

NCT05201404 Phase 3 RECRUITING

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Started: 3/15/2023

NCT06643260 Phase 3 NOT YET RECRUITING

A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

Started: 6/1/2025

NCT01235234 Phase 3 COMPLETED

Trial of CF101 to Treat Patients With Dry Eye Disease

Started: 7/1/2011

NCT03168256 Phase 3 COMPLETED

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

Started: 9/15/2018

NCT02647762 Phase 3 TERMINATED

CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

Started: 10/30/2017

NCT06387342 Phase 2 RECRUITING

Namodenoson Treatment of Advanced Pancreatic Cancer

Started: 11/10/2024

NCT04697810 Phase 2 RECRUITING

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Started: 12/10/2021

NCT07410455 Phase 2 NOT YET RECRUITING

An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome

Started: 6/1/2026

NCT02128958 Phase 2 COMPLETED

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

Started: 9/1/2014

NCT01034306 Phase 2 COMPLETED

Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

Started: 10/1/2010

NCT01033422 Phase 2 COMPLETED

Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Started: 10/1/2010

NCT04333472 Phase 2 COMPLETED

Piclidenoson for Treatment of COVID-19

Started: 1/6/2021

NCT01265667 Phase 2 COMPLETED

Trial of CF101 to Treat Patients With Psoriasis

Started: 7/1/2011

NCT02927314 Phase 2 COMPLETED

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

Started: 11/27/2017

NCT00556894 Phase 2 COMPLETED

Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients

Started: 2/1/2008

NCT00837291 Phase 2 WITHDRAWN

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

Started: 11/1/2018

NCT01905124 Phase 2 WITHDRAWN

Safety &Efficacy of CF101 to Subjects With Uveitis

Started: 1/1/2019

NCT00790218 Phase 1 COMPLETED

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

Started: 2/1/2009

NCT00790673 Phase 1 COMPLETED

A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

Started: 7/1/2009

Drug Candidates

Piclidenoson piclidenoson Placebo Namodenoson Namodenoson 25mg CF102 CF101 CF101 2mg CF101 3mg Apremilast 30mg
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 4/27/2022
Trials (12 months): 2
Completed Trials: 11
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.